                         SEQUENCE LISTING

<110>  OREGON HEALTH & SCIENCE UNIVERSITY
       VANDERBILT UNIVERSITY
       Gruber, Andras
       Tucker, Erik I.
       David, Gailani
 
<120>  ANTI-FXI ANTIBODIES AND METHODS OF USE

<130>  899-84198-02

<150>  US 61/138,590
<151>  2008-12-18

<160>  4     

<170>  PatentIn version 3.5

<210>  1
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Immunoglobulin variable light chain


<220>
<221>  MISC_FEATURE
<222>  (24)..(34)
<223>  CDR1

<220>
<221>  MISC_FEATURE
<222>  (50)..(63)
<223>  CDR2

<220>
<221>  MISC_FEATURE
<222>  (91)..(98)
<223>  CDR3

<400>  1

Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Ser Thr Ala 
            20                  25                  30          


Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Leu Thr Ser Tyr Arg Asn Thr Gly Val Pro Asp Arg Phe Thr Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Ala 
65                  70                  75                  80  


Glu Asp Leu Ala Val Tyr Tyr Cys Gln Gln His Tyr Lys Thr Pro Tyr 
                85                  90                  95      


Ser Phe Gly Gly Gly Thr Lys Leu Glu Arg Leu Arg 
            100                 105             


<210>  2
<211>  324
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Immunoglobulin variable light chain

<400>  2
gacattgtga tgacccagtc tcacaaattc atgtccacat cagtaggaga cagggtcagc       60

atcacctgca aggccagtca ggatgtgagt actgctgttg cctggtatca acagaaacca      120

ggacaatctc ctaaactact gatttacttg acatcctacc ggaacactgg agtccctgat      180

cgcttcactg gcagtggatc tgggacggat ttcactttca ccatcagcag tgtgcaggct      240

gaagacctgg cagtttacta ctgtcagcaa cattataaaa ctccgtattc gttcggaggg      300

gggaccaagc tggaacggtt acgg                                             324


<210>  3
<211>  116
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Immunoglobulin variable heavy chain


<220>
<221>  MISC_FEATURE
<222>  (31)..(35)
<223>  CDR1

<220>
<221>  MISC_FEATURE
<222>  (50)..(68)
<223>  CDR2

<220>
<221>  MISC_FEATURE
<222>  (98)..(105)
<223>  CDR3

<400>  3

Gln Val Gln Leu Glu Glu Ser Gly Pro Gly Leu Val Ala Pro Ser Gln 
1               5                   10                  15      


Ser Leu Ser Ile Thr Cys Thr Val Ser Gly Phe Ser Leu Thr Gly Tyr 
            20                  25                  30          


Gly Ile Tyr Trp Val Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Leu 
        35                  40                  45              


Gly Met Ile Trp Gly Asp Gly Arg Thr Asp Tyr Asn Ser Ala Leu Lys 
    50                  55                  60                  


Ser Arg Leu Ser Ile Ser Lys Asp Asn Ser Lys Ser Gln Val Phe Leu 
65                  70                  75                  80  


Lys Met Asn Ser Leu Gln Thr Asp Asp Thr Ala Arg Tyr Tyr Cys Ala 
                85                  90                  95      


Arg Asp Tyr Tyr Gly Ser Lys Asp Tyr Trp Gly Gln Gly Thr Thr Leu 
            100                 105                 110         


Thr Val Ser Ser 
        115     


<210>  4
<211>  348
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Immunoglobulin variable heavy chain

<400>  4
caggtgcagc tggaggagtc aggacctggc ctggtggcgc cctcacagag cctgtccatc       60

acatgcaccg tctcagggtt ctcattaacc ggctatggta tatactgggt tcgccagcct      120

ccaggaaagg gtctggagtg gctgggaatg atatggggtg atggaagaac agactataat      180

tcagctctca aatccagact gagcatcagt aaggacaact ccaagagcca agttttctta      240

aaaatgaaca gtctgcaaac tgatgacaca gccaggtact actgtgccag agattactac      300

ggtagtaagg actactgggg ccaaggcacc actctcacag tctcctca                   348


